EcoDrugPlus

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSCHAG00000017517
Gene Symbol: CYP19A1
3 Cross references
246 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSCHAG00000023596
Gene Symbol: CYP3A65
1 Cross references
606 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSCHAG00000010812
Gene Symbol: CYP3A65
1 Cross references
606 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSCHAG00000008170
Gene Symbol: CYP3A65
1 Cross references
606 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily C, Polypeptide 4

Ensembl ID : ENSCHAG00000026433
Gene Symbol: CYP3C4
1 Cross references
565 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSCHAG00000023926
Gene Symbol: LOC105904953
3 Cross references
192 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSCHAG00000007020
Gene Symbol: DGAT1B
1 Cross references
188 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSCHAG00000019823
Gene Symbol: DHODH
3 Cross references
173 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSCHAG00000010019
Gene Symbol: DPYD
3 Cross references
169 Possible Orthologues:

Dihydropyrimidine Dehydrogenase [Nadp(+)]

Ensembl ID : ENSCHAG00000023806
Gene Symbol: LOC105910742
3 Cross references
209 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSCHAG00000000563
Gene Symbol: DDR2
1 Cross references
190 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSCHAG00000025439
Gene Symbol: DDR2
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).